US5508276A
(en)
*
|
1994-07-18 |
1996-04-16 |
Eli Lilly And Company |
Duloxetine enteric pellets
|
US5910319A
(en)
|
1997-05-29 |
1999-06-08 |
Eli Lilly And Company |
Fluoxetine enteric pellets and methods for their preparation and use
|
US6199021B1
(en)
|
1997-10-15 |
2001-03-06 |
Cc Kinetics, Inc. |
Method and apparatus for measuring power output of one powering a chain driven vehicle
|
DE60023870T2
(de)
*
|
1999-04-09 |
2006-06-14 |
Lilly Co Eli |
Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
JP2005053781A
(ja)
*
|
2001-08-27 |
2005-03-03 |
Nagase & Co Ltd |
光学活性な3−(n−メチルアミノ)−1−(2−チエニル)−プロパン−1−オールの製造方法
|
EP1478641A1
(de)
*
|
2002-01-24 |
2004-11-24 |
Eli Lilly And Company |
Verfahren zur herstellung eines für die asymmetrische synthese von duloxetin geeigneten zwischenprodukts
|
US7659409B2
(en)
|
2002-03-19 |
2010-02-09 |
Mitsubishi Chemical Corporation |
3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
|
AU2003221028A1
(en)
*
|
2002-03-19 |
2003-09-29 |
Mitsubishi Chemical Corporation |
3-hydroxy-3-(2-thienyl)propionamide compound, process for producing the same, and process for producing 3-amino-1-(2-thienyl)-1-propanol compound therefrom
|
DE10212301A1
(de)
|
2002-03-20 |
2003-10-02 |
Bayer Ag |
Verfahren zur Herstellung von Aryl-aminopropanolen
|
US20060167278A1
(en)
*
|
2002-05-20 |
2006-07-27 |
Mitsubishi Rayon Co. Ltd. |
Propanolamine derivatives, process for preparation of 3-n-methylamino-1-(2-thienyl)-1-propanols and process for preparation of propanolamine derivatives
|
FR2841899A1
(fr)
*
|
2002-07-05 |
2004-01-09 |
Ppg Sipsy |
Procede de resolution asymetrique d'un racemique faisant intervenir l'acide diprogulique et utilisation dudit acide comme agent de resolution asymetrique
|
AU2003253036A1
(en)
*
|
2002-07-09 |
2004-01-23 |
Lonza Ag |
Process for the preparation of optically active 3-n-methylamino-1-(2-thienyl)-1-propanol
|
BR0312651B1
(pt)
*
|
2002-07-09 |
2017-10-31 |
Lonza Ag Lonza Sa Lonza Ltd |
Beta-amino n-monosubstitued alcohols and their preparation processes
|
EP1852415B1
(de)
*
|
2002-07-09 |
2009-10-07 |
Lonza Ag |
Verfahren zur Herstellung von N-Monoalkyl-Beta-Aminoalkoholen
|
DE10235206A1
(de)
*
|
2002-08-01 |
2004-02-19 |
Basf Ag |
Verfahren zur Herstellung von (S)-3-Methylmino-1-(thien-2-yl)propan-1-ol
|
CN1332958C
(zh)
*
|
2002-08-06 |
2007-08-22 |
住友精化株式会社 |
N-单烷基-3-羟基-3-(2-噻吩基)丙胺的制造方法及制造中间体
|
DE10237246B3
(de)
*
|
2002-08-14 |
2004-01-22 |
Consortium für elektrochemische Industrie GmbH |
(S)-3-Methylamino-1-(2-thienyl)-1-propanol-(-)-2,3,4,6-Di-O-isopropyliden-2-keto-L-gulonsäuresalz, Verfahren zu dessen Herstellung, dessen Verwendung sowie ein Verfahren zur Enantiomerenanreicherung von (S)-3-Methylamino-1-(2-thienyl)-1-propanol
|
GB0221438D0
(en)
*
|
2002-09-16 |
2002-10-23 |
Avecia Ltd |
Processes and compounds
|
AU2003276066A1
(en)
*
|
2002-10-07 |
2004-04-23 |
Lonza Ag |
Processes and intermediates for the preparation of optically active 3-amino-1-(2-thienyl)-1-propanol derivatives
|
US20040235925A1
(en)
*
|
2002-12-17 |
2004-11-25 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
GB0229583D0
(en)
|
2002-12-19 |
2003-01-22 |
Cipla Ltd |
A process for preparing duloxetine and intermediates for use therein
|
DE10302595A1
(de)
*
|
2003-01-22 |
2004-07-29 |
Basf Ag |
3-Methylamino-1-(2-thienyl)-1-proganon, seine Herstellung und Verwendung
|
AU2003263585A1
(en)
*
|
2003-08-25 |
2005-03-10 |
Hetero Drugs Limited |
Amorphous duloxetine hydrochloride
|
DE10345772A1
(de)
*
|
2003-10-01 |
2005-04-21 |
Basf Ag |
Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol
|
DE102004004719A1
(de)
*
|
2004-01-29 |
2005-08-18 |
Basf Ag |
Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen
|
BRPI0506796A
(pt)
|
2004-02-19 |
2007-05-22 |
Lonza Ag |
processo para a preparação de 1-substituìdos-3-aminoálcoois enantiomericamentente puros
|
US20050197503A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Boehringer Ingelheim International Gmbh |
Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines
|
CN1300137C
(zh)
*
|
2004-03-31 |
2007-02-14 |
上海医药工业研究院 |
(s)-(+)-n,n-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺的制备方法
|
DE102004022686A1
(de)
|
2004-05-05 |
2005-11-24 |
Basf Ag |
Verfahren zur Herstellung optisch aktiver Alkohole
|
GB0410470D0
(en)
*
|
2004-05-11 |
2004-06-16 |
Cipla Ltd |
Pharmaceutical compound and polymorphs thereof
|
CZ297560B6
(cs)
*
|
2004-10-26 |
2007-02-07 |
Zentiva, A. S. |
Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
|
CZ297555B6
(cs)
*
|
2004-10-26 |
2007-02-07 |
Zentiva, A. S. |
Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
|
JP2007523213A
(ja)
*
|
2004-12-23 |
2007-08-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
|
WO2006081515A2
(en)
*
|
2005-01-27 |
2006-08-03 |
Teva Pharmaceutical Industries Ltd. |
Duloxetine hydrochloride polymorphs
|
MX2007010931A
(es)
*
|
2005-03-08 |
2007-10-16 |
Teva Pharma |
Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
|
WO2006099433A1
(en)
*
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Pure duloxetine hydrochloride
|
WO2006126213A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Matrix Laboratories Ltd |
An improved process for the preparation of duloxetine
|
CN100364986C
(zh)
*
|
2005-07-14 |
2008-01-30 |
上海艾力斯医药科技有限公司 |
S-(+)-n,n-二甲基-3-(1-萘基氧基)-3-(2-噻吩基)丙胺的制备方法
|
JP5361187B2
(ja)
|
2005-08-19 |
2013-12-04 |
住友精化株式会社 |
(e)−n−モノアルキル−3−オキソ−3−(2−チエニル)プロペンアミンおよびその製造方法、ならびに(e,z)−n−モノアルキル−3−オキソ−3−(2−チエニル)プロペンアミンの製造方法
|
WO2007038253A2
(en)
*
|
2005-09-22 |
2007-04-05 |
Teva Pharmaceutical Industries Ltd. |
Dnt-maleate and methods of preparation thereof
|
US20080207923A1
(en)
*
|
2005-09-22 |
2008-08-28 |
Santiago Ini |
Pure DNT-maleate and methods of preparation thereof
|
PT3456329T
(pt)
|
2005-10-12 |
2025-02-25 |
Besins Healthcare Lu Sarl |
Gel de testosterona melhorado e método de utilização
|
EP2100888A3
(de)
*
|
2005-12-05 |
2011-01-19 |
Teva Pharmaceutical Industries Ltd. |
Verfahren zur Herstellung von Duloxetin-Hydrochlorid
|
EP1971591A2
(de)
*
|
2005-12-12 |
2008-09-24 |
Medichem, S.A. |
Verbesserte synthese und zubereitung von duloxetinsalzen
|
CN1304360C
(zh)
*
|
2005-12-12 |
2007-03-14 |
天津大学 |
N,n-二甲基-3-羟基-3-芳基丙胺的制备方法
|
DE102005062661A1
(de)
*
|
2005-12-23 |
2007-08-16 |
Basf Ag |
Verfahren zur Herstellung von optisch aktivem (1S)-3-Chlor-(-thien-2-yl)-propan-1-ol
|
DE102005062662A1
(de)
|
2005-12-23 |
2007-06-28 |
Basf Ag |
Verfahren zur Herstellung optisch aktiver Alkohole
|
CZ299270B6
(cs)
*
|
2006-01-04 |
2008-06-04 |
Zentiva, A. S. |
Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
|
EP1976844A4
(de)
*
|
2006-01-06 |
2010-11-03 |
Msn Lab Ltd |
Verbessertes verfahren für reines duloxetin-hydrochlorid
|
US7538232B2
(en)
|
2006-01-19 |
2009-05-26 |
Eli Lilly And Company |
Process for the asymmetric synthesis of duloxetine
|
EP1856089A1
(de)
*
|
2006-01-23 |
2007-11-21 |
Teva Pharmaceutical Industries Limited |
Dnt-succinat und herstellungsverfahren dafür
|
WO2007084194A1
(en)
*
|
2006-01-23 |
2007-07-26 |
Teva Pharmaceutical Industries Ltd. |
Dnt-benzenesulfonate and methods of preparation thereof
|
US20070191471A1
(en)
*
|
2006-01-23 |
2007-08-16 |
Santiago Ini |
DNT-fumarate and methods of preparation thereof
|
BRPI0707724A2
(pt)
*
|
2006-02-13 |
2011-05-10 |
Teva Pharma |
um novo processo para preparaÇço de (s)-(+)-n, n-dimetil-3-(1-naftaleniloxi)-3-(2-tienil)propanamina), um intermediÁrio de duloxetina
|
EP1820800A1
(de)
*
|
2006-02-17 |
2007-08-22 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Kristalline Formen von Duloxetine hydrochlorid und Verfahren zu deren Herstellung
|
WO2007098250A2
(en)
*
|
2006-02-21 |
2007-08-30 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of (s)-(-)-n,n-dimethyl-3-(2-thienyl)-3-hydroxypropanamine, a duloxetine intermediate
|
EP1826204A1
(de)
|
2006-02-28 |
2007-08-29 |
Laboratorios Del Dr. Esteve, S.A. |
Verfahren zur Herstellung enantomerer Ausgangsverbindungen von Duloxetin
|
US20080015362A1
(en)
*
|
2006-04-17 |
2008-01-17 |
Santiago Ini |
Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
|
SI1857451T1
(sl)
*
|
2006-05-05 |
2010-11-30 |
Fidia Farmaceutici |
Postopek priprave intermediata ki je uporaben zaasimetrično sintezo duloksetina
|
EP2016066A4
(de)
*
|
2006-05-10 |
2010-11-24 |
Reddys Lab Ltd Dr |
Verfahren zur herstellung von duloxetin
|
ITMI20060984A1
(it)
*
|
2006-05-18 |
2007-11-19 |
Dipharma Spa |
Procedimento per la preparazione di arilossipropilammine
|
EP1934197A2
(de)
*
|
2006-05-23 |
2008-06-25 |
Teva Pharmaceutical Industries Ltd |
Duloxetin-hcl-polymorphe
|
WO2007143065A2
(en)
*
|
2006-05-31 |
2007-12-13 |
Teva Pharmaceutical Industries Ltd. |
Process for preparing duloxetine and intermediates thereof
|
GB0612506D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Arrow Int Ltd |
Crystalline duloxetine hydrochloride
|
GB0612508D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Arrow Int Ltd |
Crystalline duloxetine hydrochloride
|
GB0612509D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Arrow Int Ltd |
Crystalline duloxetine hydrochloride
|
US20100261775A1
(en)
*
|
2006-07-03 |
2010-10-14 |
Sujoy Biswas |
Polymorphic form of duloxetine hydrochloride
|
CA2656128A1
(en)
*
|
2006-07-03 |
2008-01-10 |
Ranbaxy Laboratories Limited |
Process for the preparation of enantiomerically pure salts of n-methyl-3(1-naphthaleneoxy)-3-(2-thienyl)propanamine
|
CZ300116B6
(cs)
*
|
2006-12-05 |
2009-02-11 |
Zentiva, A. S. |
Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
|
EP2114912B1
(de)
*
|
2006-12-22 |
2012-04-04 |
Synthon B.V. |
Verfahren zur herstellung von duloxetin und verwandten verbindungen
|
WO2008081476A2
(en)
*
|
2006-12-29 |
2008-07-10 |
Cadila Healthcare Limited |
Process for preparing duloxetine hydrochloride
|
WO2008093360A2
(en)
*
|
2007-01-31 |
2008-08-07 |
Usv Limited |
A process for preparation of (s)-(+)-n-methyl-3(1-naphthyloxy)-3(2-thienyl)propylamine hydrochloride
|
WO2008107911A2
(en)
*
|
2007-03-05 |
2008-09-12 |
Lupin Limited |
Novel process for preparation of duloxetine hydrochloride
|
US8288568B2
(en)
*
|
2007-05-18 |
2012-10-16 |
Cipla Limited |
Process for the preparation of escitalopram
|
US20090017113A1
(en)
*
|
2007-07-13 |
2009-01-15 |
Osinga Niels J |
Duloxetine formulations
|
EP2060559A1
(de)
|
2007-11-19 |
2009-05-20 |
Cadila Pharmaceuticals Limited |
Herstellungsverfahren für enantiomerenreine 3-Hydroxy-3-Arylpropylamine und ihrer optischen Stereoisomere
|
WO2009087463A2
(en)
*
|
2007-12-26 |
2009-07-16 |
Orchid Chemicals & Pharmaceuticals Limited |
A method for the preparation of duloxetine hydrochloride
|
AU2009206204B2
(en)
*
|
2008-01-25 |
2015-03-19 |
Alphapharm Pty Ltd |
Delayed release pharmaceutical composition of duloxetine
|
EP2107057A1
(de)
|
2008-04-04 |
2009-10-07 |
Ranbaxy Laboratories Limited |
Verfahren zur Herstellung von reinem Duloxetin
|
AU2009234322B2
(en)
*
|
2008-04-11 |
2014-12-04 |
Nektar Therapeutics |
Oligomer-aryloxy-substituted propanamine conjugates
|
WO2009130708A2
(en)
*
|
2008-04-22 |
2009-10-29 |
Shodhana Laboratories Limited |
Preparation of duloxetine and its salts
|
US20110230666A1
(en)
*
|
2008-06-03 |
2011-09-22 |
Shodhana Laboratories Limited |
process for the separation of enantiomerically pure compounds
|
EP2133072A1
(de)
|
2008-06-13 |
2009-12-16 |
KRKA, D.D., Novo Mesto |
Magenresistente orale pharmazeutische Zusammensetzungen mit Duloxetin oder pharmazeutisch zulässigen Derivaten
|
US8426178B2
(en)
|
2008-08-27 |
2013-04-23 |
Codexis, Inc. |
Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
|
WO2010025287A2
(en)
|
2008-08-27 |
2010-03-04 |
Codexis, Inc. |
Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
|
EP2376471A4
(de)
*
|
2009-01-06 |
2012-09-12 |
Alembic Ltd |
Verbessertes verfahren zur herstellung von duloxetin und salzen davon
|
CA2754141A1
(en)
*
|
2009-03-13 |
2010-09-16 |
Alembic Pharmaceuticals Limited |
A process for the preparation of duloxetine hydrochloride
|
CZ304602B6
(cs)
|
2009-09-02 |
2014-07-30 |
Zentiva, K. S. |
Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
|
WO2011033366A2
(en)
|
2009-09-16 |
2011-03-24 |
Jubilant Life Sciences Limited |
Process for the preparation of duloxetine hydrochloride and its precursors
|
WO2011077443A1
(en)
*
|
2009-12-22 |
2011-06-30 |
Biocon Limited |
An improved process for the preparation of duloxetine hydrochloride
|
SI2558455T1
(sl)
*
|
2010-04-13 |
2017-12-29 |
Krka, D.D., Novo Mesto |
Sinteza duloksetina in/ali njegovih farmacevtsko sprejemljivih soli
|
WO2011145102A1
(en)
|
2010-05-18 |
2011-11-24 |
Arch Pharmalabs Limited |
A process for the preparation of n-methyl-o-aryloxy-propanamine derivatives and pharmaceutically acceptable salt thereof
|
US9859510B2
(en)
|
2015-05-15 |
2018-01-02 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
US11011709B2
(en)
|
2016-10-07 |
2021-05-18 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
CA3113377A1
(en)
|
2018-10-11 |
2020-04-16 |
Sanifit Therapeutics S.A. |
Inositol phosphates for the treatment of ectopic calcification
|
EP4015494A1
(de)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Verfahren zur herstellung von löslichen salzen von inositolphosphaten
|
CN114163415B
(zh)
*
|
2021-12-01 |
2023-03-03 |
珠海润都制药股份有限公司 |
一种盐酸度洛西汀中间体的制备方法
|
CN115286613B
(zh)
*
|
2022-10-08 |
2023-01-31 |
潍坊市海欣药业有限公司 |
一种盐酸度洛西汀的制备方法
|